Psoriasis is linked with a higher risk of non-alcoholic fatty liver disease, according to a new finding that will be important to note when prescribing treatments for the skin condition, researchers say. 

Doctors managing psoriasis patients need to be aware that some antipsoriatic agents, like interleukin (IL)-23, IL-17 and TNF-alpha, can damage the liver, the research team advise in JAMA Dermatology.